Moderna Covid-19 Vaccine Rna
Pediatric Systemic Lupus Erythematosus
Explore 6 assets in Pediatric Systemic Lupus Erythematosus →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Modality
vaccine
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05000216CT.gov COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pediatric Systemic Lupus Erythematosus
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Moderna Covid-19 Vaccine Rna (this asset) | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC · 53 |
| Monovalent [B.1.351] Cov2 Pres Dtm-As03 | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| Jnj-78436735 | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| Methotrexate | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| Tozinameran | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| bnt162b2 | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CC |
Other indications for Moderna Covid-19 Vaccine Rna
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Secondary Progressive Multiple Sclerosis | — | P4 | B · 62 |
| AL Amyloidosis | — | P2 | CCC · 55 |
| Neoplasm | — | P2 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Monovalent [B.1.351] Cov2 Pres Dtm-As03National Institute of Allergy and Infectious Diseases (NIAID)CCC
- Jnj-78436735National Institute of Allergy and Infectious Diseases (NIAID)CCC
- MethotrexateNational Institute of Allergy and Infectious Diseases (NIAID)CCC
- TozinameranNational Institute of Allergy and Infectious Diseases (NIAID)CCC
- bnt162b2National Institute of Allergy and Infectious Diseases (NIAID)CC
Citation
Floatz Terminal. Moderna Covid-19 Vaccine Rna in Pediatric Systemic Lupus Erythematosus. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/moderna-covid-19-vaccine-rna-pediatric-systemic-lupus-erythematosus
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →